Skip to main content
. 2019 Jun 11;11(6):275. doi: 10.3390/pharmaceutics11060275

Figure 7.

Figure 7

Release profile of RC from the optimized IFN formulations in 0.1N HCl (A), in comparison with the drug powder, and from the enteric-coated capsules containing the optimized formulations in citrate buffer (pH 6.6) (B), in comparison with the market product (Crestor® Tablets) and the drug powder.